Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Nigel Levens"'
Autor:
Valérie Audinot, L. Revereault, Antonio Monge, Susana Chamorro, O. Della-Zuana, Nigel Levens, Annette G. Beck-Sickinger, Michel Félétou, Daniel-Henri Caignard, Jean-Michel Henlin, Jean A. Boutin, Jean-Luc Fauchère
Publikováno v:
International Journal of Obesity. 28:628-639
AIM: These studies were performed to test the hypothesis that endogenous neuropeptide Y (NPY) acting on the NPY Y5 receptor subtype contributes to the control of food intake. The hypothesis was tested using S 25585—a newly synthesized NPY Y5 recept
Autor:
Michel Lonchampt, Nigel Levens, Christelle Mérial-Kieny, Jean A. Boutin, Michel Félétou, Max Lafontan, Jean-Pierre Galizzi, Verwaerde P, Francis Cogé, Jean Galitzky
Publikováno v:
British Journal of Pharmacology. 139:935-944
1. Endothelin-1 (ET-1) and tumor necrosis factor alpha (TNFalpha) by their action on adipocytes have been independently linked to the pathogenesis of insulino-resistance. In isolated adipocytes, TNFalpha induces the expression of the inducible nitric
Publikováno v:
Fundamental and Clinical Pharmacology. 17:61-69
The potency of three sulphonylureas, glibenclamide, glimepiride and gliclazide in antagonizing the vasorelaxant action of openers of adenosine triphosphate (ATP)-regulated K+ channel (KATP) was studied in vivo and in vitro in micro- and macrovessels,
Autor:
Michel Félétou, Nigel Levens, J.-P Galizzi, O. Della-Zuana, Susana Chamorro, Jean-Luc Fauchère
Publikováno v:
International Journal of Obesity. 26:281-298
AIM: The aim of this review is to critically assess available evidence that blockade of the actions of NPY at one of the five NPY receptor subtypes represents an attractive new drug discovery target for the development of an appetite suppressant drug
Autor:
F. Duchêne-Roger, Jean A. Boutin, C. Desmet-Beaufort, Jean-Luc Fauchère, Nigel Levens, Jean-Michel Henlin, Jean-Paul Nicolas
Publikováno v:
The Journal of Peptide Research. 57:419-427
Several series of low-molecular-mass ligands of the neuropeptide receptor subtype Y5 were prepared using a mixed strategy of synthesis on solid phase and in solution. Collections of single compounds were obtained by an automated parallel procedure wh
Autor:
Frederic Cumin, L Brunner, Michele Chiesi, I Leconte, S. Whitebread, A Stricker-Krongrad, Nigel Levens
Publikováno v:
International Journal of Obesity. 23:463-469
OBJECTIVE: The purpose of the present study was to investigate the continuing validity of the hypothesis that leptin is a physiologically important regulator of food intake, using the human leptin mutant R128Q leptin. DESIGN: In a cellular proliferat
Publikováno v:
International Journal of Obesity. 21:495-501
OBJECTIVE: This study was performed to test the hypothesis that the kidneys play a primary role in the clearance of endogenous leptin from the circulation of obese rats. DESIGN: Zucker (fa/fa) obese rats were anaesthetized and subjected to various su
Publikováno v:
European Journal of Pharmacology. 319:77-83
This study compared the effect of benazepril, an angiotensin converting enzyme inhibitor to valsartan, an angiotensin AT1 receptor antagonist, on glucose tolerance in the conscious, spontaneously hypertensive rat. Intraperitoneal infusion of benazepr
Publikováno v:
European Journal of Pharmacology. 294:309-317
This study tested the hypothesis that angiotensin II acting through the angiotensin AT1 receptor plays an important role in the control of gastric acid secretion. Basal gastric acid secretion and gastric blood flow were lower in Na(+)-depleted animal
Autor:
Nigel Levens, Marc de Gasparo
Publikováno v:
Kidney International. 46:1486-1491
Pharmacology of angiotensin II receptors in the kidney. Within the kidney angiotensin II (Ang II) exerts potent effects on renal function. The intrarenal actions of Ang II include modulation of renal blood flow, glomerular filtration rate, tubular ep